Drugs that contain Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate
1. List of Genvoya drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US7176220 | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(3 years from now) | |
| US8981103 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| US7635704 | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(3 years from now) | |
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 1 month ago) | |
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
|
US7176220
(Pediatric) | GILEAD SCIENCES INC | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(3 years from now) | |
|
US7635704
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
|
US8981103
(Pediatric) | GILEAD SCIENCES INC | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(4 years from now) | |
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(6 years from now) | |
|
US9891239
(Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(6 years from now) | |
|
US8148374
(Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(6 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(7 years from now) | |
|
US8633219
(Pediatric) | GILEAD SCIENCES INC | Combination therapy |
Oct, 2030
(7 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(9 years from now) | |
|
US10039718
(Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(10 years from now) | |
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
GENVOYA family patents
65
United States
36
European Union
35
Japan
23
Norway
17
Spain
17
Australia
15
Portugal
15
China
15
Korea, Republic of
15
Hungary
14
Lithuania
13
Croatia
13
Slovenia
13
Denmark
12
New Zealand
12
Hong Kong
12
Cyprus
11
Canada
11
Poland
10
Argentina
9
Singapore
9
Mexico
9
EA
8
Brazil
8
Taiwan, Province of China
7
AP
7
RS
6
South Africa
6
ME
6
Ukraine
5
Peru
5
Israel
4
Luxembourg
3
Colombia
3
Czech Republic
3
Ecuador
2
Turkey
2
Malaysia
2
Uruguay
2
Russia
2
San Marino
2
Chile
2
Netherlands
1
Germany
1
Moldova, Republic of
1
Costa Rica
1
Estonia
1
Austria
1
Morocco
1
Belgium
1
India
1
Slovakia
1
Bulgaria
1
Iceland
1
OA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic